{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:42:44Z","timestamp":1792456964660,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-026-03018-w","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:54:23Z","timestamp":1784861663000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipoprotein(a) and adverse cardiovascular outcomes in dialysis patients: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Ioannis","family":"Bellos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smaragdi","family":"Marinaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Benetou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"3018_CR1","doi-asserted-by":"crossref","unstructured":"Cozzolino M, Mangano M, Stucchi A, Ciceri P, Conte F, Galassi A. Cardiovascular disease in dialysis patients. Nephrol Dial Transplant. 2018;33:iii28\u201334. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30281132\/. Cited 23 May 2026.","DOI":"10.1093\/ndt\/gfy174"},{"key":"3018_CR2","doi-asserted-by":"crossref","unstructured":"Echefu G, Stowe I, Burka S, Basu-Ray I, Kumbala D. Pathophysiological concepts and screening of cardiovascular disease in dialysis patients. Front Nephrol. 2023;3. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37840653\/. Cited 23 May 2026.","DOI":"10.3389\/fneph.2023.1198560"},{"key":"3018_CR3","doi-asserted-by":"crossref","unstructured":"Naki\u0107 D, Grbi\u0107 Pavlovi\u0107 P, Vojkovi\u0107 M, Stip\u0107evi\u0107 M, Patrk J, Bi\u0161tirli\u0107 M et al. Coronary Artery Disease in Patients on Dialysis: Impact of Traditional Risk Factors. Medicina (Kaunas). 2024;60. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/39202533\/. Cited 23 May 2026.","DOI":"10.3390\/medicina60081251"},{"key":"3018_CR4","doi-asserted-by":"crossref","unstructured":"Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P et al. Lipid management in patients with chronic kidney disease. Nat Rev Nephrol. 2018;14:727\u201349. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30361677\/. Cited 23 May 2026.","DOI":"10.1038\/s41581-018-0072-9"},{"key":"3018_CR5","doi-asserted-by":"crossref","unstructured":"Barbagallo CM, Cefal\u00f9 AB, Giammanco A, Noto D, Caldarella R, Ciaccio M et al. Lipoprotein Abnormalities in Chronic Kidney Disease and Renal Transplantation. Life (Basel, Switzerland). 2021;11. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33916487\/. Cited 23 May 2026.","DOI":"10.3390\/life11040315"},{"key":"3018_CR6","doi-asserted-by":"crossref","unstructured":"Hasan YK, Alsultan M, Anan MT, Hassn Q, Basha K. The prevalence of dyslipidemia in patients on hemodialysis: a cross-sectional study from Syria. Ann Med Surg. 2023;85:3838\u201344. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37554881\/. Cited 23 May 2026.","DOI":"10.1097\/MS9.0000000000000931"},{"key":"3018_CR7","doi-asserted-by":"crossref","unstructured":"Liu Y, Wang R, Li S, Zhang C, Lip GYH, Thabane L et al. Relationship Between Lipoprotein(a), Renal Function Indicators, and Chronic Kidney Disease: Evidence From a Large Prospective Cohort Study. JMIR public Heal Surveill. 2024;10. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38294877\/. Cited 23 May 2026.","DOI":"10.2196\/50415"},{"key":"3018_CR8","doi-asserted-by":"crossref","unstructured":"Hopewell JC, Haynes R, Baigent C. The role of lipoprotein (a) in chronic kidney disease. J Lipid Res. 2018;59:577\u201385. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29378781\/. Cited 23 May 2026.","DOI":"10.1194\/jlr.R083626"},{"key":"3018_CR9","doi-asserted-by":"crossref","unstructured":"Richardson T, Gardner M, Salani M. Cardiovascular Disease and Dialysis: A Review of the Underlying Mechanisms, Methods of Risk Stratification, and Impact of Dialysis Modality Selection on Cardiovascular Outcomes. Kidney Dial 2025, Vol 5, Page 5. 2025;5:5. Available from: https:\/\/www.mdpi.com\/2673-8236\/5\/1\/5\/htm. Cited 23 May 2026.","DOI":"10.3390\/kidneydial5010005"},{"key":"3018_CR10","doi-asserted-by":"crossref","unstructured":"Abidor E, Achkar M, Al Saidi I, Lather T, Jdaidani J, Agarwal A et al. Comprehensive Review of Lipid Management in Chronic Kidney Disease and Hemodialysis Patients: Conventional Approaches, and Challenges for Cardiovascular Risk Reduction. J Clin Med. 2025;14. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/39860649\/. Cited 23 May 2026.","DOI":"10.3390\/jcm14020643"},{"key":"3018_CR11","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33782057\/.\u00a0\u00a0Cited 22 May 2026."},{"key":"3018_CR12","doi-asserted-by":"crossref","unstructured":"Greenhalgh T, Peacock R. Effectiveness and efficiency of search methods in systematic reviews of complex evidence: audit of primary sources. BMJ. 2005;331:1064\u20135. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16230312\/. Cited 22 May 2026.","DOI":"10.1136\/bmj.38636.593461.68"},{"key":"3018_CR13","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Morgan RL, Rooney AA, Taylor KW, Thayer KA, Silva RA et al. A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E). Environ Int. 2024;186. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38555664\/. Cited 22 May 2026.","DOI":"10.1016\/j.envint.2024.108602"},{"key":"3018_CR14","doi-asserted-by":"crossref","unstructured":"Tanriver-Ayder E, Faes C, Van De Casteele T, McCann SK, Macleod MR. Comparison of commonly used methods in random effects meta-analysis: application to preclinical data in drug discovery research. BMJ Open Sci. 2021;5:e100074. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8647574\/. Cited 22 May 2026.","DOI":"10.1136\/bmjos-2020-100074"},{"key":"3018_CR15","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/12958120\/. Cited 22 May 2026.","DOI":"10.1136\/bmj.327.7414.557"},{"key":"3018_CR16","doi-asserted-by":"crossref","unstructured":"Foroutan F, Guyatt G, Zuk V, Vandvik PO, Alba AC, Mustafa R et al. GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. J Clin Epidemiol. 2020;121:62\u201370. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31982539\/. Cited 22 May 2026.","DOI":"10.1016\/j.jclinepi.2019.12.023"},{"key":"3018_CR17","doi-asserted-by":"crossref","unstructured":"Ioannidis JPA. Interpretation of tests of heterogeneity and bias in meta-analysis. J Eval Clin Pract. 2008;14:951\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19018930\/. Cited 22 May 2026.","DOI":"10.1111\/j.1365-2753.2008.00986.x"},{"key":"3018_CR18","doi-asserted-by":"crossref","unstructured":"Longenecker JC, Klag MJ, Marcovina SM, Powe NR, Fink NE, Giaculli F et al. Small apolipoprotein(a) size predicts mortality in end-stage renal disease: The CHOICE study. Circulation. 2002;106:2812\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/12451008\/. Cited 22 May 2026.","DOI":"10.1161\/01.CIR.0000038946.91899.BB"},{"key":"3018_CR19","doi-asserted-by":"crossref","unstructured":"Koch M, Kutkuhn B, Grabensee B, Ritz E. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects. Nephrol Dial Transplant. 1997;12:2603\u201311. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/9430859\/.\u00a0Cited 22 May 2026.","DOI":"10.1093\/ndt\/12.12.2603"},{"key":"3018_CR20","doi-asserted-by":"crossref","unstructured":"Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648\u201358. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/9987089\/. Cited 22 May 2026.","DOI":"10.1046\/j.1523-1755.1999.00273.x"},{"key":"3018_CR21","doi-asserted-by":"crossref","unstructured":"Kronenberg F, Neyer U, Lhotta K, Trenkwalder E, Auinger M, Pribasnig A et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol. 1999;10:1027\u201336. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/10232689\/. Cited 22 May 2026.","DOI":"10.1681\/ASN.V1051027"},{"key":"3018_CR22","doi-asserted-by":"crossref","unstructured":"Kim SB, Lee SK, Park JS, Moon DH. Prevalence of coronary artery disease using thallium-201 single photon emission computed tomography among patients newly undergoing chronic peritoneal dialysis and its association with mortality. Am J Nephrol. 2004;24:448\u201352. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/15308878\/. Cited 22 May 2026.","DOI":"10.1159\/000080220"},{"key":"3018_CR23","doi-asserted-by":"crossref","unstructured":"Hocher B, Ziebig R, Altermann C, Krause R, Asmus G, Richter CM et al. Different impact of biomarkers as mortality predictors among diabetic and nondiabetic patients undergoing hemodialysis. J Am Soc Nephrol. 2003;14:2329\u201337. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/12937310\/. Cited 22 May 2026.","DOI":"10.1097\/01.ASN.0000081662.64171.9B"},{"key":"3018_CR24","doi-asserted-by":"crossref","unstructured":"Koch M, Gradaus F, Schoebel FC, Leschke M, Grabensee B. Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy. Nephrol Dial Transplant. 1997;12:1187\u201391. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/9198049\/. Cited 22 May 2026.","DOI":"10.1093\/ndt\/12.6.1187"},{"key":"3018_CR25","doi-asserted-by":"crossref","unstructured":"Koch M, Kutkuhn B, Trenkwalder E, Bach D, Grabensee B, Dieplinger H et al. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol. 1997 ;8:1889\u201398. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/9402091\/. Cited 22 May 2026.","DOI":"10.1681\/ASN.V8121889"},{"key":"3018_CR26","doi-asserted-by":"crossref","unstructured":"Emanuele E, Lusignani LS, Peros E, Montagna G, D\u2019Angelo A, Montagna L et al. Lipoprotein(a)-associated atherothrombotic risk in hemodialysis patients. Am J Nephrol. 2004;24:221\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/15017119\/.\u00a0\u00a0Cited 22 May 2026.","DOI":"10.1159\/000077293"},{"key":"3018_CR27","doi-asserted-by":"crossref","unstructured":"Xu LC, Zhou FF, Li M, Dai ZW, Lin HX, Zhu BX et al. The Correlation between Serum Lipoprotein(a) and Risk of Mortality in Patients on Peritoneal Dialysis. Clin Lab. 2022;68:1717\u201327. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35975486\/. Cited 22 May 2026.","DOI":"10.7754\/Clin.Lab.2022.220102"},{"key":"3018_CR28","doi-asserted-by":"crossref","unstructured":"Sameiro-Faria M, Do, Ribeiro S, Costa E, Mendon\u00e7a D, Teixeira L, Rocha-Pereira P et al. Risk factors for mortality in hemodialysis patients: two-year follow-up study. Dis Markers. 2013;35:791\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24347799\/. Cited 22 May 2026.","DOI":"10.1155\/2013\/518945"},{"key":"3018_CR29","doi-asserted-by":"crossref","unstructured":"Liang Q, Zhang G, Jiang L. Association between lipoprotein (a) and risk of atherosclerotic cardiovascular disease events among maintenance hemodialysis patients in Beijing, China: a single-center, retrospective study. BMC Nephrol. 2024 ;25. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/39090533\/. Cited 22 May 2026.","DOI":"10.1186\/s12882-024-03690-z"},{"key":"3018_CR30","doi-asserted-by":"publisher","unstructured":"Ambe M, Sunohara K, Tayasu M, Takanashi M, Kozaki Y, Nagaya H et al. Elevated lipoproten(a) levels at dialysis initiation predict cardiovascular events: a single-center, retrospective cohort study. Ren Replace Ther 2025 111. 2025;11:97-. Available from: https:\/\/link.springer.com\/article\/https:\/\/doi.org\/10.1186\/s41100-025-00692-x. Cited 22 May 2026.","DOI":"10.1186\/s41100-025-00692-x"},{"key":"3018_CR31","doi-asserted-by":"crossref","unstructured":"Chen Y, Zhan X, Zhao Q, Wei X, Xiao J, Yan C et al. Serum lipoprotein(a) and risk of hemorrhagic stroke among incident peritoneal dialysis patients: a large study from a single center in China. Ren Fail. 2019;41:800\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31498021\/. Cited 22 May 2026.","DOI":"10.1080\/0886022X.2019.1659151"},{"key":"3018_CR32","doi-asserted-by":"crossref","unstructured":"Kollerits B, Drechsler C, Krane V, Lamina C, M\u00e4rz W, Dieplinger H et al. Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study. Nephrol Dial Transplant. 2016;31:1901\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26754832\/. Cited 22 May 2026.","DOI":"10.1093\/ndt\/gfv428"},{"key":"3018_CR33","doi-asserted-by":"crossref","unstructured":"Liang Q, Zhang G, Jiang L, Li B, Song K. Lipoprotein(a) levels and cardiovascular mortality risk in Chinese patients undergoing hemodialysis. Int Urol Nephrol. 2025 ;57:2669\u201379. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/40128433\/. Cited 22 May 2026.","DOI":"10.1007\/s11255-025-04459-5"},{"key":"3018_CR34","doi-asserted-by":"crossref","unstructured":"Longenecker JC, Klag MJ, Marcovina SM, Liu YM, Jaar BG, Powe NR et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol. 2005;16:1794\u2013802. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/15800123\/. Cited 22 May 2026.","DOI":"10.1681\/ASN.2004110922"},{"key":"3018_CR35","doi-asserted-by":"crossref","unstructured":"Zhong Z, Peng F, Shi D, Peng Y, Li B, Xiao M et al. Serum lipoprotein(a) and risk of mortality in patients on peritoneal dialysis. J Clin Lipidol. 2020;14:252\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32081604\/. Cited 22 May 2026.","DOI":"10.1016\/j.jacl.2020.01.008"},{"key":"3018_CR36","doi-asserted-by":"crossref","unstructured":"Ohashi H, Oda H, Ohno M, Watanabe S, Sakata S. Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients. Kidney Int. 1999;56:S242\u20134. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0085253815466529. Cited 22 May 2026.","DOI":"10.1046\/j.1523-1755.1999.07164.x"},{"key":"3018_CR37","doi-asserted-by":"crossref","unstructured":"Collado S, Coll E, Nicolau C, Pons M, Cruzado JM, Pascual J et al. Carotid atherosclerotic disease predicts cardiovascular events in hemodialysis patients: a prospective study. PLoS One. 2015;10. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26029907\/. Cited 22 May 2026.","DOI":"10.1371\/journal.pone.0127344"},{"key":"3018_CR38","doi-asserted-by":"crossref","unstructured":"Cressman MD, Abood D, O\u2019Neil J, Hoff HF. Lp(a) and premature mortality during chronic hemodialysis treatment. Chem Phys Lipids. 1994;67\u201368:419\u201327. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/8187242\/. Cited 22 May 2026.","DOI":"10.1016\/0009-3084(94)90165-1"},{"key":"3018_CR39","doi-asserted-by":"crossref","unstructured":"Cressman MD, Heyka RJ, Paganini EP, O\u2019Neil J, Skibinski CI, Hoff HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation. 1992;86:475\u201382. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/1386292\/. Cited 22 May 2026.","DOI":"10.1161\/01.CIR.86.2.475"},{"key":"3018_CR40","doi-asserted-by":"crossref","unstructured":"Goldwasser P, Michel MA, Collier J, Mittman N, Fein PA, Gusik SA et al. Prealbumin and Lipoprotein(a) in Hemodialysis: Relationships With Patient and Vascular Access Survival. Am J Kidney Dis. 1993;22:215\u201325. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/8322786\/. Cited 22 May 2026.","DOI":"10.1016\/S0272-6386(12)70189-0"},{"key":"3018_CR41","doi-asserted-by":"crossref","unstructured":"Hishikari K, Hikita H, Yoshikawa H, Abe F, Tsujihata S, Ito N et al. Usefulness of Lipoprotein (a) for Predicting Outcomes After Percutaneous Coronary Intervention for Stable Angina Pectoris in Patients on Hemodialysis. Am J Cardiol. 2020;136:32\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32941820\/. Cited 22 May 2026.","DOI":"10.1016\/j.amjcard.2020.08.049"},{"key":"3018_CR42","doi-asserted-by":"crossref","unstructured":"Iliescu EA, Marcovina SM, Morton AR, Lam M, Koschinsky ML. Apolipoprotein(a) phenotype and lipoprotein(a) level predict peritoneal dialysis patient mortality. Perit Dial Int. 2002;22:492\u20139. Available from: https:\/\/doi.org\/10.1177\/089686080202200408?download=true. Cited 22 May 2026.","DOI":"10.1177\/089686080202200408"},{"key":"3018_CR43","unstructured":"Ishikawa H. [Lipoprotein (a) is a risk factor for cerebrovascular accident in patients with chronic renal failure]. Nihon Jinzo Gakkai Shi. 1994;36:846\u201352. Available from: https:\/\/europepmc.org\/article\/med\/8072223. Cited 22 May 2026."},{"key":"3018_CR44","unstructured":"Koda Y, Nishi SI, Suzuki M, Hirasawa Y. Lipoprotein(a) is a predictor for cardiovascular mortality of hemodialysis patients. Kidney Int Suppl. 1999;71. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/10412791\/. Cited 22 May 2026."},{"key":"3018_CR45","doi-asserted-by":"crossref","unstructured":"Boffa MB, Koschinsky ML. Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? J Lipid Res. 2016;57:745\u201357. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26647358\/. Cited 22 May 2026.","DOI":"10.1194\/jlr.R060582"},{"key":"3018_CR46","doi-asserted-by":"crossref","unstructured":"Lampsas S, Xenou M, Oikonomou E, Pantelidis P, Lysandrou A, Sarantos S et al. Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment. Molecules. 2023;28. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36770634\/. Cited 22 May 2026.","DOI":"10.3390\/molecules28030969"},{"key":"3018_CR47","doi-asserted-by":"crossref","unstructured":"Florens N, Calzada C, Lyasko E, Juillard L, Soulage CO. Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins. Toxins (Basel). 2016;8:376. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5198570\/. Cited 22 May 2026.","DOI":"10.3390\/toxins8120376"},{"key":"3018_CR48","doi-asserted-by":"crossref","unstructured":"Hopewell JC, Haynes R, Baigent C. The role of lipoprotein (a) in chronic kidney disease. J Lipid Res. 2018;59:577\u201385. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29378781\/. Cited 22 May 2026.","DOI":"10.1194\/jlr.R083626"},{"key":"3018_CR49","doi-asserted-by":"crossref","unstructured":"Frischmann ME, Kronenberg F, Trenkwalder E, Schaefer JR, Schweer H, Dieplinger B et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int. 2007;71:1036\u201343. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/17299521\/. Cited 22 May 2026.","DOI":"10.1038\/sj.ki.5002131"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-026-03018-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-026-03018-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-026-03018-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:35:37Z","timestamp":1792456537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-026-03018-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3018"],"URL":"https:\/\/doi.org\/10.1186\/s12944-026-03018-w","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"1 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not needed. This study is a systematic review that is exclusively based on previously published data. No new participants were recruited.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"212"}}